Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Clover Health appoints Robert Torricelli and Brian Miller to board, filling two vacancies

Neutral Impact 2 of 5 leadership Written later

Clover Health's Board appointed former U.S. Senator Robert Torricelli as a Class I director and Dr. Brian J. Miller as a Class III director, effective September 22, 2026. The appointments fill the Board's two previously disclosed vacancies and bring the Board to nine directors, with Torricelli joining the Audit Committee and Miller joining the Clinical Committee.

Key points

  • Senator Robert G. Torricelli appointed Class I director and to the Audit Committee
  • Dr. Brian J. Miller appointed Class III director and to the Clinical Committee
  • Each director to receive a restricted stock unit award valued at $200,000, pro-rated through December 31, 2026
  • Board size increases to nine directors; each will enter the company's standard indemnification agreement

The filing

CompanyCLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
Form8-K, current report
Filed with the SECSep 24, 2026, 4:31 PM ET
Accession number0001801170-26-000229

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.